These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 28667076)
1. RNA Editing in Pathogenesis of Cancer. Baysal BE; Sharma S; Hashemikhabir S; Janga SC Cancer Res; 2017 Jul; 77(14):3733-3739. PubMed ID: 28667076 [TBL] [Abstract][Full Text] [Related]
2. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic. Ganem NS; Ben-Asher N; Lamm AT Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975 [TBL] [Abstract][Full Text] [Related]
3. RNA editing, epitranscriptomics, and processing in cancer progression. Witkin KL; Hanlon SE; Strasburger JA; Coffin JM; Jaffrey SR; Howcroft TK; Dedon PC; Steitz JA; Daschner PJ; Read-Connole E Cancer Biol Ther; 2015; 16(1):21-7. PubMed ID: 25455629 [TBL] [Abstract][Full Text] [Related]
5. Hydrolytic nucleoside and nucleotide deamination, and genetic instability: a possible link between RNA-editing enzymes and cancer? Anant S; Davidson NO Trends Mol Med; 2003 Apr; 9(4):147-52. PubMed ID: 12727140 [TBL] [Abstract][Full Text] [Related]
6. Transient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes. Sharma S; Patnaik SK; Kemer Z; Baysal BE RNA Biol; 2017 May; 14(5):603-610. PubMed ID: 27149507 [TBL] [Abstract][Full Text] [Related]
7. ADARs and editing: The role of A-to-I RNA modification in cancer progression. Fritzell K; Xu LD; Lagergren J; Öhman M Semin Cell Dev Biol; 2018 Jul; 79():123-130. PubMed ID: 29146145 [TBL] [Abstract][Full Text] [Related]
8. Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer. Lee SH; Kim HP; Kang JK; Song SH; Han SW; Kim TY Cancer Res Treat; 2017 Oct; 49(4):1077-1087. PubMed ID: 28161934 [TBL] [Abstract][Full Text] [Related]
9. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Han L; Diao L; Yu S; Xu X; Li J; Zhang R; Yang Y; Werner HMJ; Eterovic AK; Yuan Y; Li J; Nair N; Minelli R; Tsang YH; Cheung LWT; Jeong KJ; Roszik J; Ju Z; Woodman SE; Lu Y; Scott KL; Li JB; Mills GB; Liang H Cancer Cell; 2015 Oct; 28(4):515-528. PubMed ID: 26439496 [TBL] [Abstract][Full Text] [Related]
10. To edit or not to edit: regulation of ADAR editing specificity and efficiency. Deffit SN; Hundley HA Wiley Interdiscip Rev RNA; 2016; 7(1):113-27. PubMed ID: 26612708 [TBL] [Abstract][Full Text] [Related]
11. The emerging role of RNA and DNA editing in cancer. Avesson L; Barry G Biochim Biophys Acta; 2014 Apr; 1845(2):308-16. PubMed ID: 24607277 [TBL] [Abstract][Full Text] [Related]
13. The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme. Sharma S; Patnaik SK; Taggart RT; Baysal BE Sci Rep; 2016 Dec; 6():39100. PubMed ID: 27974822 [TBL] [Abstract][Full Text] [Related]
14. A-to-I RNA editing and cancer: from pathology to basic science. Gallo A; Galardi S RNA Biol; 2008; 5(3):135-9. PubMed ID: 18758244 [TBL] [Abstract][Full Text] [Related]
15. Diverse functions for DNA and RNA editing in the immune system. Hamilton CE; Papavasiliou FN; Rosenberg BR RNA Biol; 2010; 7(2):220-8. PubMed ID: 20220309 [TBL] [Abstract][Full Text] [Related]